// App-Quantinova.ai

560 : Multicenter phase Ib/II study of everolimus (RAD001) and tivozanib (AV-951) in patients with refractory, metastatic colorectal cancer.

Researchers

Presenter

  • Brian M. Wolpin

Principal Investigators

  • Kimmie Ng

  • Andrew X. Zhu

  • Jennifer A. Chan

  • Wolfram Goessling

  • Lawrence Scott Blaszkowsky

  • Meaghan Elliott

  • Maria Shellock

  • Eileen Regan

  • Charles S. Fuchs

  • Thomas Adam Abrams

  • Peter C. Enzinger

  • Nadine McCleary

  • Jeffrey A. Meyerhardt

  • Deborah Schrag

  • Eunice Lee Kwak

  • Jill N. Allen

  • Pankaj Bhargava

Medical Centers

  • ARIAD Pharmaceuticals, Inc., Cambridge, MA

  • Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA

  • Department of Pathology, Massachusetts General Hospital, Boston, MA

  • Dana-Farber Cancer Institute, Boston, MA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Gastroenterology (GU)

Disease

  • Colorectal Cancer

  • Venous thrombosis

  • Gastrointestinal stromal tumor

  • Solid malignancies

Biomarkers

  • KRAS proto-oncogene, GTPase

Drug/Treatment

  • Bevacizumab

  • Oxaliplatin

  • Everolimus

  • Irinotecan

  • Tivopath

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved